DK3307299T3 - Kombinationssammensætninger til behandling af lidelser krævende fjernelse eller ødelæggelse af uønskede celleformeringer - Google Patents

Kombinationssammensætninger til behandling af lidelser krævende fjernelse eller ødelæggelse af uønskede celleformeringer Download PDF

Info

Publication number
DK3307299T3
DK3307299T3 DK16730498.9T DK16730498T DK3307299T3 DK 3307299 T3 DK3307299 T3 DK 3307299T3 DK 16730498 T DK16730498 T DK 16730498T DK 3307299 T3 DK3307299 T3 DK 3307299T3
Authority
DK
Denmark
Prior art keywords
destruction
treatment
unwanted cell
combination compositions
required removal
Prior art date
Application number
DK16730498.9T
Other languages
English (en)
Inventor
Paul Averback
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Application granted granted Critical
Publication of DK3307299T3 publication Critical patent/DK3307299T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK16730498.9T 2015-06-12 2016-06-13 Kombinationssammensætninger til behandling af lidelser krævende fjernelse eller ødelæggelse af uønskede celleformeringer DK3307299T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/738,551 US20160361380A1 (en) 2015-06-12 2015-06-12 Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
PCT/IB2016/053483 WO2016199112A1 (en) 2015-06-12 2016-06-13 Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations

Publications (1)

Publication Number Publication Date
DK3307299T3 true DK3307299T3 (da) 2021-03-22

Family

ID=56137476

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16730498.9T DK3307299T3 (da) 2015-06-12 2016-06-13 Kombinationssammensætninger til behandling af lidelser krævende fjernelse eller ødelæggelse af uønskede celleformeringer

Country Status (22)

Country Link
US (1) US20160361380A1 (da)
EP (1) EP3307299B1 (da)
JP (1) JP6941605B2 (da)
KR (1) KR20180035788A (da)
CN (1) CN108135974A (da)
AU (1) AU2016275368B2 (da)
CA (1) CA2992174A1 (da)
DK (1) DK3307299T3 (da)
EA (1) EA038314B1 (da)
ES (1) ES2876358T3 (da)
HK (1) HK1254080A1 (da)
HR (1) HRP20210462T1 (da)
HU (1) HUE053665T2 (da)
IL (1) IL256230B (da)
LT (1) LT3307299T (da)
MX (1) MX2017016106A (da)
PL (1) PL3307299T3 (da)
PT (1) PT3307299T (da)
RS (1) RS61685B1 (da)
SI (1) SI3307299T1 (da)
WO (1) WO2016199112A1 (da)
ZA (1) ZA201800083B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11628202B2 (en) * 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
WO2019055648A1 (en) * 2017-09-14 2019-03-21 Tufts Medical Center, Inc. METHOD OF TREATMENT AND DIAGNOSIS OF PROSTATE CANCER
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423507A (en) 1966-02-25 1969-01-21 Schering Corp Method of treating benign prostratic hypertrophy
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4329364A (en) 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE2817157A1 (de) 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
FR2465486A1 (fr) 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3121153A1 (de) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4760053A (en) 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4659695A (en) 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4775660A (en) 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
FR2582513B1 (fr) 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5212176A (en) 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
IL101243A (en) 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
WO1994008040A1 (en) 1992-09-25 1994-04-14 Synaptic Pharmaceutical Corporation Dna encoding human alpha 1 adrenergic receptors and uses thereof
US5403847A (en) 1992-11-13 1995-04-04 Synaptic Pharmaceutical Corporation Use of α1C specific compounds to treat benign prostatic hyperlasia
WO1996014846A1 (en) 1994-11-16 1996-05-23 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
WO2000028004A1 (en) 1998-11-10 2000-05-18 The University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
KR100632903B1 (ko) 2001-03-08 2006-10-13 니목스 파마슈티칼스 코포레이션 신경 사 단백질을 사용하여 종양 및 세포의 제거 또는파괴를 필요로 하는 다른 증상을 치료하는 방법
CA2446480A1 (en) * 2001-05-04 2002-11-14 Nymox Corporation Method of preventing cell death using antibodies to neural thread proteins
ATE300951T1 (de) * 2001-05-16 2005-08-15 Nymox Corp Prävention des zelltodes durch verwendung der segmente der neurofilamentproteine
EP1390403B1 (en) 2001-05-25 2007-01-03 Nymox Corporation Peptides derived from neural thread proteins and their medical use
CN100432103C (zh) * 2001-07-19 2008-11-12 尼莫克斯股份有限公司 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽
DE60218179T2 (de) * 2001-07-19 2007-11-22 Nymox Corp., Saint-Laurent Peptide zur behandlung von tumoren und anderen bedingungen, die die entfernung oder zerstörung von zellen erfordern
EP1714979A3 (en) * 2001-11-16 2007-04-25 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
DK1961418T3 (da) * 2005-11-15 2012-07-23 Cheng Jingcai Anvendelse af isothiocyanatforbindelser til behandling af prostatasygdomme og hudcancer
SI1994152T1 (sl) * 2006-02-28 2013-05-31 Nymox Corporation Peptidi uäśinkoviti pri zdravljenju tumorjev in ostalih stanj, ki zahtevajo odstranitev ali uniäśenje celic
US20070237780A1 (en) 2006-03-10 2007-10-11 Paul Averback Method of preventing or reducing the risk or incidence of cancer
ES2634669T3 (es) * 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
CA2905438A1 (en) * 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses

Also Published As

Publication number Publication date
LT3307299T (lt) 2021-04-12
EA038314B1 (ru) 2021-08-09
ES2876358T3 (es) 2021-11-12
AU2016275368A1 (en) 2018-02-01
PL3307299T3 (pl) 2021-07-05
IL256230A (en) 2018-02-28
MX2017016106A (es) 2018-08-01
EP3307299B1 (en) 2020-12-23
JP6941605B2 (ja) 2021-09-29
RS61685B1 (sr) 2021-05-31
IL256230B (en) 2021-04-29
CA2992174A1 (en) 2016-12-15
KR20180035788A (ko) 2018-04-06
JP2018517772A (ja) 2018-07-05
PT3307299T (pt) 2021-03-26
CN108135974A (zh) 2018-06-08
ZA201800083B (en) 2019-07-31
EA201890045A1 (ru) 2018-05-31
WO2016199112A1 (en) 2016-12-15
HK1254080A1 (zh) 2019-07-12
HRP20210462T1 (hr) 2021-05-14
HUE053665T2 (hu) 2021-07-28
EP3307299A1 (en) 2018-04-18
US20160361380A1 (en) 2016-12-15
SI3307299T1 (sl) 2021-04-30
AU2016275368B2 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
DK3307299T3 (da) Kombinationssammensætninger til behandling af lidelser krævende fjernelse eller ødelæggelse af uønskede celleformeringer
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3349758T3 (da) Fremgangsmåder til behandling af arenaviridae-virusinfektioner
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3234145T3 (da) Fremgangsmåde til kontrollered aktivering eller eliminering af terapeutiske celler
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
DK3600270T3 (da) Forbindelser og sammensætninger til behandling af hæmatologiske lidelser
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3492632T3 (da) Metoder til behandling af lithiumholdige materialer
DK3285803T3 (da) Fremgangsmåder til behandling eller forebyggelse af migrænehovedpine
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3102213T3 (da) Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
DK3203997T3 (da) Valproinsyre til behandling eller forebyggelse af patologiske tilstande forbundet med overskydende fibrinaflejring og/eller trombedannelse
DK3524255T3 (da) Sammensætning til behandling af acne
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3134084T3 (da) Fremgangsmåde til behandling af lungeadenokarcinom
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3081263T3 (da) Sammensætninger og redskaber til behandling af glaukom
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
DK3261661T3 (da) Menotropin til behandling af infertilitet
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi